Theratechnologies (TSX:TH) ROCE % : -26.15% (As of Feb. 2024)

View and export this data going back to 1998. Start your Free Trial

What is Theratechnologies ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Theratechnologies's annualized ROCE % for the quarter that ended in Feb. 2024 was -26.15%.

Theratechnologies ROCE % Historical Data

The historical data trend for Theratechnologies's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theratechnologies ROCE % Chart

Theratechnologies Annual Data

Trend

Nov14

Nov15

Nov16

Nov17

Nov18

Nov19

Nov20

Nov21

Nov22

Nov23

ROCE %

Get a 7-Day Free Trial

-9.13

-24.76

-38.60

-167.16

-267.80

Theratechnologies Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
ROCE %	Get a 7-Day Free Trial															-	-1,610.62	-	-	-26.15

Theratechnologies ROCE % Calculation

Theratechnologies's annualized ROCE % for the fiscal year that ended in Nov. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Nov. 2023 )		(A: Nov. 2022 )		(A: Nov. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Nov. 2023 )		(A: Nov. 2022 )		(A: Nov. 2023 )
	=	-18.059	/	( ( (125.5 - 153.785)	+	(106.598 - 64.826) )	/ 2 )
	=	-18.059	/	( (-28.285	+	41.772)	/ 2 )
	=	-18.059	/	6.7435
	=	-267.80 %

Theratechnologies's ROCE % of for the quarter that ended in Feb. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Feb. 2024 )		(Q: Nov. 2023 )		(Q: Feb. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Feb. 2024 )		(Q: Nov. 2023 )		(Q: Feb. 2024 )
	=	-9.304	/	( ( (106.598 - 64.826)	+	(97.322 - 67.925) )	/ 2 )
	=	-9.304	/	( ( 41.772	+	29.397 )	/ 2 )
	=	-9.304	/	35.5845
	=	-26.15 %

(1) Note: The EBIT data used here is four times the quarterly (Feb. 2024) EBIT data.

Theratechnologies (TSX:TH) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Theratechnologies ROCE % Related Terms

Thank you for viewing the detailed overview of Theratechnologies's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Theratechnologies (TSX:TH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theratechnologies Inc (TSX:TH) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

THTX:USA TQ80:Germany

Address

2015, rue Peel, 11e etage, Montreal, QC, CAN, H3A 1T8

Website

https://www.theratech.com

Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States.

Executives

Joseph Arena	Director
Philippe Dubuc	Senior Officer
Gérald A. Lacoste	Director
Paul Lévesque	Senior Officer
Andrew Molson	Director
Dawn Svoronos	Director
John Leasure	Senior Officer